Valneva SE (VIE:VLA)
Austria · Delayed Price · Currency is EUR | Market Cap | 471.27M -43.6% |
| Revenue (ttm) | 142.94M -27.2% |
| Net Income | -157.65M |
| EPS | -0.88 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292 |
| Open | 2.487 |
| Previous Close | 2.602 |
| Day's Range | 2.461 - 2.504 |
| 52-Week Range | 2.048 - 5.115 |
| Beta | 1.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial StatementsNews
UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide
(RTTNews) - Valneva SE (VALN), a speciality vaccine company, announced that after a further benefit-risk assessment of IXCHIQ for travellers by the United Kingdom's (UK) Commission on Human Medicines ...
Valneva SE (VALN) Shares Drop After UK Revokes Chikungunya Vaccine Authorization
Valneva SE (VALN) Shares Drop After UK Revokes Chikungunya Vaccine Authorization
MHRA Revokes UK Marketing Authorization for Valneva's Ixchiq (VALN)
MHRA Revokes UK Marketing Authorization for Valneva's Ixchiq (VALN)
Valneva announces Ixchiq marketing authorization revoked by UK MHRA
Valneva (VALN) announced that, following a further benefit-risk assessment of Ixchiq for travelers by the United Kingdom’s Commission on Human Medicines, or CHM, the UK marketing authorization for Ixc...
Valneva Provides Update on IXCHIQ® in the United Kingdom
Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for traveler...
Valneva (VALN) Q2 2026 Earnings Call Transcript
Restructuring efforts and Lyme vaccine regulatory timeline take center stage.
Pfizer, Valneva announce EMA validation for PF-07307405 MAA
Pfizer (PFE) and Valneva (VALN) announced that the European Medicines Agency, or EMA, has validated the marketing authorization application, or MAA, for PF-07307405, the companies’ 6-valent outer surf...
Valneva Stock (VLN) Soars Over 20% On Lyme Disease Vaccine Hopes
Shares in biotech Valneva ($VALN) soared over 20% in early trading today after it and partner Pfizer ($PFE) as it moved closer to bringing its Lyme disease vaccine to Europe.
Pfizer And Valneva's Lyme Vaccine Clears EMA Review Gate
(RTTNews) - Pfizer Inc. (PFE) and Valneva SE's (VALN) Lyme disease vaccine candidate has reached a key regulatory milestone, with the European Medicines Agency (EMA) validating the companies' Marketin...
Pfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA
(RTTNews) - Pfizer Inc. (PFE) and Valneva SE (VALN) said Friday that the European Medicines Agency (EMA) has validated their Marketing Authorization Application for PF-07307405, a Lyme disease vaccine...
Pfizer Inc.: Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medi...
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketin...
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-0...
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketin...
Valneva Q2 Earnings Call Highlights
Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectatio...
Valneva SE Earnings Call Transcript: Q2 2026
H1 2026 saw lower revenues and higher losses due to non-recurring costs and restructuring, but cash position improved. Guidance for 2026 is reaffirmed, with financial self-sustainability targeted for 2027, pending Lyme vaccine approval. Pfizer filed for EMA review, and R&D pipeline progress continues.
Valneva SE Earnings release: Q2 2026
Valneva SE released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Valneva SE Slides: Q2 2026
Valneva SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Valneva SE Earnings release: Q2 2026
Valneva SE released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Valneva SE Quarterly report: Q2 2026
Valneva SE has published its Q2 2026 quarterly earnings report on August 13, 2026.
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year...
Valneva initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Valneva (VALN) with a Buy rating and $12 price target The company’s base vaccine business offers downside protection, while LB6V is a “de-risked” Lyme disease…
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, Augus...
Experimental vaccine shows promise against dangerous intestinal illness
New ETEC vaccine technology targeting enterotoxigenic Escherichia coli has been licensed to Valneva after decades of research at University of Bergen.
Valneva SE Slides: Company presentation
Valneva SE has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.